Alnylam Pharmaceuticals Q3 revenue rises on AMVUTTRA demand
Overview
RNAi therapeutics firm's Q3 net product revenue rose 52% yr/yr, driven by AMVUTTRA demand
Company expanded TRITON-CM Phase 3 study enrollment for nucresiran
Outlook
Alnylam reiterates 2026 total net product revenue guidance of $4.7 bln to $5.1 bln
Company expects 2026 TTR net product revenues of $4.2 bln to $4.5 bln
Alnylam forecasts 2026 Rare net product revenues of $500 mln to $600 mln
Result Drivers
AMVUTTRA DEMAND - Co said Q3 revenue growth was mainly driven by increased patient demand for AMVUTTRA, especially in ATTR-CM in the U.S.
INVENTORY AND PRICING - Co said U.S. TTR revenue growth benefited from inventory adjustments and favorable gross-to-net pricing in Q3
INTERNATIONAL LAUNCHES - Co said international TTR revenue growth was driven by ATTR-CM launches in Japan, Germany, and Italy
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Adjusted EPS | $16.26 | ||
Q3 Adjusted Net Income | $2.24 bln | ||
Q3 Net Income | $2.17 bln | ||
Q3 Adjusted Operating income | $424.92 mln | ||
Q3 Operating Income | $345.80 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 24 "strong buy" or "buy", 8 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Alnylam Pharmaceuticals, Inc. is $350.00, about 50.6% above its October 28 closing price of $232.40
The stock recently traded at 26 times the next 12-month earnings vs. a P/E of 33 three months ago
Reuters Recommended Reads
Oct 28 - Biogen tops quarterly estimates on rare-disease drug strength
Oct 29 - Eli Lilly lifts revenue outlook on weight-loss drug sales, trims profit view on deal charges
Oct 28 - Viking Therapeutics posts bigger-than-expected Q3 loss as costs rise
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)